US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

WisdomTree Global ex U.S. Quality Dividend Growth Fund

43.89

-0.1200-0.27%

Post-market: 43.890.00000.00%16:10 EDT

Volume:24.67K

Turnover:1.08M

Market Cap:469.62M

PE:- -

High:44.10

Open:44.10

Low:43.64

Close:44.01

52wk High:45.33

52wk Low:34.62

Shares:10.70M

Float Shares:10.70M

Volume Ratio:0.68

T/O Rate:0.23%

Dividend:0.75

Dividend Rate:1.71%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Is Dyno Nobel’s (ASX:DNL) Aggressive Buy-Back Quietly Rewriting Its Earnings Story?

Simply Wall St.

Dyno Nobel (ASX:DNL) shareholders have earned a 12% CAGR over the last five years

Simply Wall St.

Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne

Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DNL"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DNL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DNL\",,,,,undefined,":{"symbol":"DNL","market":"US","secType":"STK","nameCN":"WisdomTree Global ex U.S. Quality Dividend Growth Fund","latestPrice":43.89,"timestamp":1776369600000,"preClose":44.01,"halted":0,"volume":24670,"hourTrading":{"tag":"盘后","latestPrice":43.89,"preClose":43.89,"latestTime":"16:10 EDT","volume":10,"amount":438.9,"timestamp":1776370204368,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0027266530334014417,"floatShares":10700000,"shares":10700000,"eps":0,"marketStatus":"Not Yet Opened","change":-0.12,"latestTime":"04-16 16:00:00 EDT","open":44.1,"high":44.1,"low":43.64,"amount":1080243.562813,"amplitude":0.010452,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1776412800000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":44.01,"sharesOutstanding":10900000,"nav":43.687521,"aum":467456470.59,"dividendRate":0.017147,"bidAskSpread":0.002666,"preHourTrading":{"tag":"盘前","latestPrice":44.01,"preClose":44.01,"latestTime":"08:07 EDT","volume":1,"amount":44.01,"timestamp":1776341229418,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":43.89,"preClose":43.89,"latestTime":"16:10 EDT","volume":10,"amount":438.9,"timestamp":1776370204368,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.675528,"impliedVol":0.075,"impliedVolPercentile":0.664},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DNL\",,,,,undefined,":{"symbol":"DNL","floatShares":10700000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.675528,"shares":10700000,"dividePrice":0.7526,"high":44.1,"amplitude":0.010452,"preClose":44.01,"low":43.64,"week52Low":34.62481,"pbRate":"--","week52High":45.33,"institutionHeld":0,"latestPrice":43.89,"eps":0,"divideRate":0.017147,"volume":24670,"delay":0,"ttmEps":0,"open":44.1,"prevYearClose":41.22,"prevWeekClose":42.94,"prevMonthClose":40.37,"prevQuarterClose":40.37,"fiveDayClose":42.6413,"twentyDayClose":40.895,"sixtyDayClose":42.415},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DNL\",params:#limit:5,,,undefined,":[{"date":"2026-03-26","symbol":"DNL","amount":0.02,"announcedDate":"2026-03-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-26","defaultRemindTime":1774531800000,"name":"WisdomTree Global ex U.S. Quality Dividend Growth Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-30","payableDate":"2026-03-26","currency":"USD","dateTimestamp":1774497600000,"payDate":"2026-03-30"},{"date":"2025-12-26","symbol":"DNL","amount":0.23418,"announcedDate":"2025-12-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-26","defaultRemindTime":1766759400000,"name":"WisdomTree Global ex U.S. Quality Dividend Growth Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-30","payableDate":"2025-12-26","currency":"USD","dateTimestamp":1766725200000,"payDate":"2025-12-30"},{"date":"2025-09-25","symbol":"DNL","amount":0.17,"announcedDate":"2025-09-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-25","defaultRemindTime":1758807000000,"name":"WisdomTree Global ex U.S. Quality Dividend Growth Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-29","payableDate":"2025-09-25","currency":"USD","dateTimestamp":1758772800000,"payDate":"2025-09-29"},{"date":"2025-06-25","symbol":"DNL","amount":0.33,"announcedDate":"2025-06-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-25","defaultRemindTime":1750858200000,"name":"WisdomTree Global ex U.S. Quality Dividend Growth Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-25","currency":"USD","dateTimestamp":1750824000000,"payDate":"2025-06-27"},{"date":"2025-03-26","symbol":"DNL","amount":0.115,"announcedDate":"2025-03-25","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-26","defaultRemindTime":1742995800000,"name":"WisdomTree Global ex U.S. Quality Dividend Growth Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-28","payableDate":"2025-03-26","currency":"USD","dateTimestamp":1742961600000,"payDate":"2025-03-28"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DNL\",market:\"US\",,,undefined,":[{"executeDate":"2016-06-20","recordDate":"2016-06-22","paymentDate":"2016-06-24","value":0.485,"currency":"USD"},{"executeDate":"2016-09-26","recordDate":"2016-09-28","paymentDate":"2016-09-30","value":0.395,"currency":"USD"},{"executeDate":"2016-12-23","recordDate":"2016-12-28","paymentDate":"2016-12-30","value":0.18202,"currency":"USD"},{"executeDate":"2017-03-27","recordDate":"2017-03-29","paymentDate":"2017-03-31","value":0.15,"currency":"USD"},{"executeDate":"2017-06-26","recordDate":"2017-06-28","paymentDate":"2017-06-30","value":0.335,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DNL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DNL\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2619105961","title":"Is Dyno Nobel’s (ASX:DNL) Aggressive Buy-Back Quietly Rewriting Its Earnings Story?","url":"https://stock-news.laohu8.com/highlight/detail?id=2619105961","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619105961?lang=en_us&edition=fundamental","pubTime":"2026-03-15 17:20","pubTimestamp":1773566429,"startTime":"0","endTime":"0","summary":"In recent months, Dyno Nobel’s parent Incitec Pivot has continued an on-market buy-back of its ordinary fully paid shares, repurchasing more than 43 million shares as of 12 March 2026 to manage capital and support shareholder value.\nThis steady reduction in the share count is reshaping the company’s capital structure and could meaningfully influence future earnings per share calculations for investors.\nWe’ll now examine how this ongoing on-market buy-back, and its impact on share count, may...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/2022000-choice1-main-header/1585186586604","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2022000-choice1-main-header/1585186586604"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-dnl/dyno-nobel-shares/news/is-dyno-nobels-asxdnl-aggressive-buy-back-quietly-rewriting","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-dnl/dyno-nobel-shares/news/is-dyno-nobels-asxdnl-aggressive-buy-back-quietly-rewriting","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DNL.AU","DNL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611144980","title":"Dyno Nobel (ASX:DNL) shareholders have earned a 12% CAGR over the last five years","url":"https://stock-news.laohu8.com/highlight/detail?id=2611144980","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611144980?lang=en_us&edition=fundamental","pubTime":"2026-02-15 07:16","pubTimestamp":1771111002,"startTime":"0","endTime":"0","summary":"These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But you can do a...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/2022000-choice1-main-header/1585186586604","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2022000-choice1-main-header/1585186586604"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-dnl/dyno-nobel-shares/news/dyno-nobel-asxdnl-shareholders-have-earned-a-12-cagr-over-th","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-dnl/dyno-nobel-shares/news/dyno-nobel-asxdnl-shareholders-have-earned-a-12-cagr-over-th","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DNL","DNL.AU","BK7025"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608866680","title":"Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne","url":"https://stock-news.laohu8.com/highlight/detail?id=2608866680","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608866680?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:00","pubTimestamp":1770033600,"startTime":"0","endTime":"0","summary":"SAN MATEO, Calif., Feb.  02, 2026  (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabol","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/02/3230125/0/en/Sagimet-Announces-Positive-52-Week-Data-from-License-Partner-Ascletis-Open-Label-Phase-3-Clinical-Trial-Evaluating-the-Long-Term-Safety-of-ASC40-Denifanstat-Tablets-in-Patients-wit.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNL","IGA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607208545","title":"Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne","url":"https://stock-news.laohu8.com/highlight/detail?id=2607208545","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607208545?lang=en_us&edition=fundamental","pubTime":"2026-01-29 19:00","pubTimestamp":1769684400,"startTime":"0","endTime":"0","summary":"- Denifanstat , aonce-daily oral fatty acid synthase  inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study. - The exceptional efficacy of denifanstat  observed in the Company's previously reported placebo-controlled Phase III trial coupled with a favorable safety profile in two Phase III trials provide a potential major break-through for the treatment of acne. - New Drug Application for denifanstat  for acne was recently accepted by the China National Medical Products Administration. HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Ascletis Pharma Inc.  today announced positive topline results from the Phase III open-label study  evaluating denifanstat , a first-in-class, once-daily oral small molecule fatty acid synthase  inhibitor, in patients with moderate-to-severe acne vulgaris.Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ascletis-announces-positive-topline-results-from-its-phase-iii-open-label-study-of-denifanstat-asc40-a-first-in-class-once-daily-oral-fasn-inhibitor-for-acne-302673870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNL.AU","DNL","BK4134","III","BK7025"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/DNL\",params:#limit:6,delay:false,,,undefined,":[]}}